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Summary
Hepatitis C virus (HCV) infected patients often take multiple co-
medications to treat adverse events related to HCV therapy, or
to manage other co-morbidities. Drug–drug interactions associ-
ated with this polypharmacy are relatively new to the ﬁeld of
HCV pharmacotherapy. With the advent of the direct-acting
antivirals telaprevir and boceprevir, which are both substrates
and inhibitors of the cytochrome P450 (CYP) 3A iso-enzyme,
knowledge and awareness of drug–drug interactions have
become a cornerstone in the evaluation of patients starting and
continuing HCV combination therapy. In our opinion, an over-
view of conducted drug–drug interaction studies and a list of
contraindicated medications is not enough for the clinical man-
agement of these drug–drug interactions. Knowledge of pharma-
cokinetic proﬁles and concentration–effect relationships is key
for the interpretation of these data, and insight into how to man-
age these interactions (e.g., dose adjustments, safe alternatives
and therapeutic drug monitoring) is of equal importance. This
review provides a practical overview of the safe and effective
management of these clinical challenges.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Introduction
With the introduction of the direct-acting antivirals (DAAs)
telaprevir and boceprevir in Europe, US and other countries in
2011–2012, the management of drug–drug interactions in the
treatment of patients with hepatitis C virus (HCV) has gained
wide interest. Drug–drug interactions were not entirely new to
the ﬁeld, as certain combinations of ribavirin and human immu-
nodeﬁciency virus (HIV) nucleoside analogues had been shown to
be problematic before [1], and transplant hepatologists have long
learned to consider drug–drug interactions with ciclosporin and
tacrolimus. The current attention on drug–drug interactions
and their clinical management, however, is unprecedented in
hepatology and many other disease areas, and can only be com-
pared to the introduction of HIV-protease inhibitors in the
mid-90s.
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• With the advent of the direct-acting antivirals telaprevir
and boceprevir, knowledge and awareness of drug-
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Table 1. Overview of drug interactions with frequently used co-medications in HCV-infected patients. (See below-mentioned references for further information.)
Interacting agent Anti-HCV agent CI Management (M)
Alternative (A)
[Ref.]
Alfusozin (ALF) BOC, TVR Y
Alprazolam (ALP) BOC, TVR M: monitor for toxicity ALP
A: oxazepam
[23]
Amiodarone (AMI) BOC M: monitor for toxicity AMI
TVR Y
Amlodipine (AML) TVR M: monitor for toxicity AML; start with 5 mg of AML
A: BOC
[24]
Atorvastatin (ATO) TVR Y A: pravastatin [24]
BOC M: monitor for toxicity ATO, maximum of 20 mg ATO/day
A: pravastatin
[25]
Azathioprin (AZA) RBV Y
Bosentan (BOS) BOC, TVR M: monitor for toxicity BOS
Budesonide (BUD) 
inhalation, intranasally
BOC, TVR Y A: beclomethasone
Carbamazepin (CAR) BOC, TVR Y A: valproic acid, lamotrigine, levetiracetam
Ciclosporin (CIC) TVR M: reduce CIC dose and/or extend dose interval; monitor CIC levels
A: boceprevir and monitor CIC levels
[11, 12]
Clarithromycin (CLA) BOC, TVR M: monitor for toxicity CLA and TVR
A: azithromycine
Colchicine (COL) BOC, TVR M: monitor for toxicity COL; reduce dose of COL, see product label 
HCV PI
Dabigatran (DAB) TVR M: monitor for toxicity DAB
Dexamethasone (DEX) BOC, TVR
Digoxin (DIG) TVR M: monitor for toxicity DIG; start with low dose and monitor DIG levels [22]
BOC M: monitor DIG levels [27]
Diltiazem (DIL) BOC, TVR M: monitor for toxicity DIL
A: low-dose amlodipine
Disopyramide (DIS) TVR Y
Domperidone (DOM) BOC, TVR Y A: metoclopramide
Drosperinone (DRO) BOC Y
Ergotamin (ERG) BOC, TVR Y
Erythromycin (ERY) BOC, TVR M: monitor for toxicity ERY and TVR
A: azithromycine
Escitalopram (ESC) TVR
A: BOC
[21]
Ethinylestradiol (EE) BOC, TVR Y M: use two non-hormonal types of contraception [28]
Felodipine (FEL) BOC, TVR M: monitor for toxicity FEL
A: low-dose amlodipine
Flecainide (FLE) BOC, TVR M: monitor for toxicity FLE
Fluticasone (FLU) inhalation, 
intranasally
BOC, TVR Y A: beclamethasone
Halofantrin (HAL) BOC, TVR Y
Ibutilide (IBU) TVR Y
Imatinib (IMT) BOC, TVR Y
Itraconazole (ITR) BOC, TVR M: monitor for toxicity ITR and HCV PI; maximum of 200 mg ITR/day
Ketoconazole (KET) BOC, TVR M: monitor for toxicity KET and HCV PI; maximum 200 mg KET/day [15]
Lidocain (LID), IV BOC, TVR M: monitor for toxicity LID
Lumefantrin (LUM) BOC, TVR Y
Methadone (MET) BOC, TVR [17]
IFN M: monitor for toxicity MET [29]
Methylprednisolone (MPR) BOC, TVR Y
Midazolam (MID), PO BOC, TVR Y A: temazepam or lorazepam or parenteral midazolam [22, 2]
M: monitor for efficacy HCV PI
M: monitor for efficacy ESC, increase ESC dose if needed
A: fluconazole
A: fluconazole
M: monitor for efficacy MET
(continued on next page)
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Each health professional involved with HCV treatment (hepa-
tologist, infectious disease specialist, nurse specialist, clinical
pharmacist, etc.) will need a sound and complete understanding
of the potential of a drug–drug interaction in every patient trea-
ted for HCV infection. This is a rapidly evolving ﬁeld and many
questions on speciﬁc drug combinations remain unanswered.
Most of the drug–drug interaction studies are initially presented
at conferences and many do not appear in peer-reviewed
literature. Besides knowledge on potential mechanisms that form
the basis of the development of drug–drug interactions, one
should also have an overview of the most frequently occurring
or most serious potential drug combinations. Finally, awareness
of how to ﬁnd reliable and up-to-date information is essential.
One of the reliable and up-to-date sources is a website from
the University of Liverpool: www.hep-druginteractions.org.
However, since only a small number of interactions have been
Midazolam (MID), IV BOC, TVR M: reduce IV dose with 50% [22]
Nicardipine (NIC) BOC, TVR M: monitor for toxicity NIC
A: low-dose amlodipine
Nifedipine (NIF) BOC, TVR M: monitor for toxicity NIF
A: low-dose amlodipine
Nisoldipine (NIS) BOC, TVR M: monitor for toxicity NIS
A: low-dose amlodipine
Phenobarbital (PHB) BOC, TVR Y A: valproic acid, lamotrigine, levetiracetam
Phenytoine (PHT) BOC, TVR Y A: valproic acid, lamotrigine, levetiracetam
Pimozide (PIM) BOC, TVR Y
Propafenon (PRF) BOC, TVR M: monitor for toxicity PRF
Posaconazole (POS) BOC, TVR M: monitor for toxicity HCV PI
Prednisone (PRE) BOC, TVR Y
Quinidine (QID) BOC M: monitor for toxicity QID
TVR Y
Rifabutin (RFB) BOC, TVR Y
Rifampin (RIF) BOC, TVR Y [15]
Salmeterol (SAL) BOC, TVR Y A: formoterol
BOC, TVR M: maximum of 25 mg SIL/48 h 
Simvastatine (SIM) BOC, TVR Y A: pravastatin or BOC with low-dose atorvastatin
Sirolimus (SIR) BOC, TVR Y
Sorafenib (SOR) BOC, TVR Y
Sotalol (SOT) TVR Y
St John’s Wort (SJW) BOC, TVR Y
Sunitinib (SUT) BOC, TVR Y
Tacrolimus (TAC) TVR Y [11]
BOC M: reduce TAC dose and/or extend dose interval; monitor TAC levels
A: ciclosporin
[12]
BOC, TVR M: maximum of 10 mg TAD/72 h
Telbivudine (TEL) IFN Y
Telithromycine (TEL) BOC, TVR M: monitor for toxicity TEL and TVR
A: azithromycine
Theophyllin (THE) IFN M: monitor for toxicity THE, monitor THE levels
Trazodone (TRA) BOC, TVR M: monitor for toxicity TRA, start with low-dose TRA
Triazolam (TRI) BOC, TVR Y A: temazepam of lorazepam
TVR M: maximum of 2.5 mg VAR/72 h
BOC M: maximum of 2.5 mg VAR/24 h
Verapamil (VER) BOC, TVR M: monitor for toxicity VER
A: low-dose amlodipine
Voriconazole (VOR) TVR Y
BOC M: monitor for toxicity BOC and VOR
Warfarin (WAR) BOC, TVR
Zolpidem (ZOL) TVR [23]
Interacting agent Anti-HCV agent CI Management (M)
Alternative (A)
[Ref.]
M: monitor for efficacy ZOL
M: monitor for toxicity and efficacy WAR; monitor INR
A: fluconazole
Vardenafil (VAR)
Tadalafil (TAD)
Sildenafil (SIL)
A: fluconazol
CI, contraindicated; BOC, boceprevir; TVR, telaprevir; RBV, ribavirin; IFN, interferon; IV, intravenous; HCV PI, hepatitis C virus protease inhibitor; INR, international
normalized ratio; Y, yes.
Table 1 (continued)
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studied, one of the challenges is to provide expert opinion on
potential interactions based on metabolic data and an under-
standing of the mechanisms. Currently, the website does not
always provide information on effective alternatives when faced
with a problematic interaction, and this would be a useful
addition.
In this paper, we will review drug interactions with HCV
agents and a number of therapeutic groups. As (potential) drug
interactions between HIV and HCV drugs are extensive [2], it
was decided that this deserves a separate review and, therefore,
this will not be included here. Also, alternative and complemen-
tary medicines (e.g., herbals) may cause drug interactions but
have not yet been studied and are consequently not the scope
of this paper. Before discussion of potential drug interactions
with anti-HCV agents, the pharmacokinetic properties of the
drugs and current knowledge of their concentration–effect
relationships will be discussed. This basic knowledge is required
for an adequate interpretation of drug interaction data. It is
important to remember that drug–drug interactions can be bidi-
rectional, i.e., both drugs are affected.
Data on drug interactions were extracted from published liter-
ature, Summaries of Product Characteristics (SPCs) [3,4], abstract
books from medical conferences, and clinical experience. If possi-
ble, a safe alternative is given to manage a speciﬁc drug interac-
tion although it should be noted that clinical experience is
limited. Data have been updated until July 1, 2012 and this over-
view is restricted to licensed anti-HCV agents.
Pharmacokinetics of anti-HCV agents
This paragraph focuses on the currently available anti-HCV
agents ribavirin, polyethylene glycol (Peg)-interferon alfa, tela-
previr and boceprevir. Ribavirin is a nucleoside analogue and as
such a prodrug requiring intracellular activation to a triphos-
phate. Ribavirin-triphosphate accumulates in red blood cells
because these cells lack the enzyme to degrade the triphosphate.
Ribavirin has a bioavailability of approximately 64%, which is lar-
gely dependent on simultaneous intake of food. Absorption is
dose-limited, so it is recommended to take ribavirin twice-daily
(BID), although based on its long elimination half-life (approxi-
mately 300 h) less frequent dosing might have been more logical.
Ribavirin is not metabolised by hepatic enzymes and does not
inﬂuence hepatic metabolism of other agents. It is eliminated
unchanged by the kidneys.
Interferon alfa is a recombinant representative of a natural
protein that can only be administered parenterally; its pharmaco-
kinetic proﬁle is improved by encapsulation of the molecule in a
peg ‘‘coat’’. As a result, dosing frequency could be reduced to
once-weekly subcutaneous administration. There are 2 forms
marketed: 2a and 2b, which have limited pharmacokinetic differ-
ences, and in this paper interferon alfa is meant to represent both
2a and 2b products. Peg-interferon alfa is not a substrate of hepa-
tic metabolism and does not show a direct inducing or inhibitory
effect on hepatic metabolism of other agents.
Boceprevir and telaprevir are both orally available HCV prote-
ase inhibitors with food-dependent absorption and relatively
short elimination half-lives, necessitating three times daily
administration (BID administration of telaprevir is currently in
phase III clinical trial). Both agents are substrates of CYP3A,
although for boceprevir this is not the primary route of
metabolism; boceprevir is primarily metabolised by aldo–ketore-
ductases (AKR) and only a minor proportion is subject to CYP3A-
mediated metabolism [5]. Both boceprevir and telaprevir are
substrates of the membrane transporter P-glycoprotein (P-gp),
which is present at many sites, including the gastro-intestinal
tract, blood–brain barrier, placenta; P-gp is a so-called efﬂux
pump and prevents uptake of substrates, and as such can be seen
as a protection of the body against noxious substances. Telaprevir
and boceprevir are both strong inhibitors of CYP3A, with telapre-
vir being associated with a stronger inhibitory effect than boce-
previr (see data on immunosuppressants and midazolam
below). Both agents also appear to be inhibitors of P-gp (again,
with boceprevir being a weaker inhibitor than telaprevir, based
on digoxin data), but it should be noted that this is more difﬁcult
to assess as a large overlap between CYP3A and P-gp substrates
exists. Both agents are so-called mechanism-based inhibitors of
CYP3A, which means that CYP3A is inactivated. As a consequence,
reduced CYP3A activity is maintained even when telaprevir or
boceprevir use is discontinued, until new CYP3A enzymes are
generated (approximately 1 week).
Based on the above, much attention will be directed to inter-
actions between boceprevir/telaprevir on one hand and CYP3A/
P-gp substrates/inhibitors/inducers on the other hand.
Concentration, effect relationships
It is difﬁcult to interpret results from drug–drug interaction stud-
ies without a detailed insight into concentration–response rela-
tionships. If there is no change in plasma concentrations when
drug A is added to drug B, one can easily conclude that both
agents can be safely combined from a pharmacokinetic perspec-
tive. But what changes in drug concentrations is generally
accepted to be related to reduced efﬁcacy: 30%,50% or
70%? At which elevated drug concentration is the risk for toxic-
ity signiﬁcantly increased? Which pharmacokinetic parameter is
most closely associated with therapeutic response and thus
should be used for interpretation: the average exposure to the
drug during one dose interval (area-under-the-concentration vs.
time curve, AUC), or for instance the trough concentration (Cmin)?
A sensible statement can only be made if a concentration–effect
relationship is known, there is some idea of a target concentra-
tion, how far away the ‘‘average’’ patient is from this putative
threshold and how large the interpatient variability is in pharma-
cokinetics. It is not surprising that in clinical practice such a
well-balanced and thorough evaluation of drug interaction data
is hardly possible, and inevitably we have to look at drug interac-
tion data outcomes in a more general way. Regulatory bodies
such as the Food and Drug Administration (FDA) or European
Medicines Agency (EMA) could decide that any reduction in
exposure of more than a certain percentage (i.e., 30%, 40%, 50%)
could be deﬁned as clinically relevant, and hence any combina-
tion of drugs that leads to this kind of plasma drug concentration
change should lead to either a dose adjustment or a contraindica-
tion. Such a general condition can then be applied to agents with
comparable mechanisms of action and pharmacokinetic proper-
ties. This is, however, difﬁcult to justify given differences in
concentration, effect relationships and is currently not an FDA
or EMA viewpoint.
Another important consideration is that in pharmacokinetic
studies, plasma (or serum) pharmacokinetic parameters are
assessed, while it is known that anti-HCV agents are primarily
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active inside the hepatocyte and not in plasma. Hepatocytes,
however, do not represent an easily accessible biological matrix.
Animal data may not always reﬂect the human situation, as there
are differences in expression of uptake transporters between spe-
cies [6]. As a result, we tend to assume that globally, there is a
correlation between concentrations at the site of activity and in
plasma, and hence changes in plasma concentrations will result
in more or less similar changes inside the hepatocyte. For all
DAAs, correlations have been found between plasma concentra-
tions and HCV RNA decline after the start of treatment [7,8]. Thus,
the assumption that plasma concentrations are a surrogate for
levels inside the hepatocyte appears valid so far. However, in
individual patients, there could be a ‘‘mismatch’’ between plasma
and hepatocyte concentrations, for instance caused by genetic
polymorphisms in uptake or efﬂux transporters present on the
cell membrane of a hepatocyte. Another example of a mismatch
could be for nucleoside analogues that are activated intracellu-
larly to triphosphates: plasma concentrations of the parent com-
pound may not always be related to intracellular concentrations
of the triphosphate.
A further important aspect is the possibility to use therapeutic
drug monitoring (TDM) to assess the presence of a clinically rel-
evant drug interaction. TDM can play a major role in the manage-
ment of a drug–drug interaction and to evaluate the effectiveness
of an intervention such as a dose adjustment. For anti-HCV
agents, this is currently only possible for ribavirin in a number
of specialized laboratories. Literature suggests that steady-state
plasma concentrations of ribavirin at week 8 or later should be
2.0 mg/L or higher to reduce the risk of virological failure as much
as possible [9]. If a drug interaction with ribavirin is known or
suspected, this may lead to changes in ribavirin plasma concen-
trations and TDM can then be recommended. TDM is also possi-
ble, and probably indispensible, for a number of therapeutic
groups that are inﬂuenced by HCV protease inhibitors, such as
immunosuppressants and antiretroviral agents. But also in other
situations the adagium ‘‘one dose does not ﬁt all’’ can be advo-
cated to understand whether a drug interaction is causing inter-
or intrapatient variability in drug concentrations. Currently, TDM
of HCV protease inhibitors telaprevir and boceprevir is not yet
possible because of practical issues around blood sampling, stor-
age of samples, limited availability of pure compounds, etc. In
addition, TDM comes at a cost and tends only to be performed
in specialist centers.
Immunosuppressive agents (including steroids)
Without doubt one of the most important drug interactions with
the currently available anti-HCV agents are those with immuno-
suppressants, such as tacrolimus and ciclosporin [10]. These
immunosuppressants are substrates of both CYP3A and P-gp
and, with the above-described inhibitory effects of boceprevir
and telaprevir on CYP3A and P-gp, it was expected that the
plasma concentrations of the immunosuppressants would be
largely increased. In particular, the interaction between tacroli-
mus and telaprevir has a magnitude that is unprecedented in
clinical pharmacology: the AUC of tacrolimus is increased by
70.3-fold and this combination would be lethal if doses are not
adjusted [11]. Ciclosporin levels are increased ‘‘only’’ 4.1-fold
when combined with telaprevir. Also for boceprevir, the interac-
tion with tacrolimus is stronger than for ciclosporin, but
differences are less pronounced than for telaprevir: tacrolimus
levels increase 17-fold and ciclosporin levels 2.6-fold when com-
bined with boceprevir [12]. Less attention has been paid to the
effects of the immunosuppressants on the levels of the HCV pro-
tease inhibitors, but no inﬂuence is expected.
The above-mentioned data have been collected in healthy
volunteers; preliminary data presented at EASL 2012 suggest
that with TDM of immunosuppressants directly from the start
of combined treatment these combinations are indeed manage-
able with adjusted doses that appear to be around 50% of the
observed differences in healthy volunteers [13]. Overall, the
ciclosporin dose needed to be adjusted by an average factor of
1.3 while the interaction study in healthy volunteers showed
a 2.6-fold increase. However, in this study, patients were admit-
ted to hospital for correction of drug dosing and intensively
monitored. Phase II studies are ongoing that might allow less
intensive monitoring and more ﬂexible dosing of the immuno-
suppressants, for instance a very low dose of tacrolimus taken
once-a-week when combined with telaprevir. At the current
time, there is some uncertainty whether the safety and efﬁcacy
of tacrolimus once weekly (with telaprevir) can be extrapolated
from daily use of tacrolimus (without telaprevir), even when
similar target trough levels of tacrolimus are achieved. The com-
bination of ciclosporin and boceprevir causes the smallest inter-
action and could be considered a preferred option. There are no
data on the use of other immunosuppressants such as sirolimus
and everolimus, but it is expected that the effects are similar to
those with tacrolimus.
Systemically applied corticosteroids such as prednisone and
methylprednisolone are CYP3A substrates and higher steroid lev-
els may occur when combined with telaprevir and boceprevir,
and this is not recommended. This also holds true for corticoste-
roids that are locally applied by inhalation or intranasally such as
budesonide and ﬂuticasone: Cushing syndrome may occur with
DAAs. Regarding the systemic glucocorticoid dexamethasone,
this agent can act as an enzyme inducer and may be associated
with low DAA levels. There are data available suggesting that
beclomethasone can be used safely in patients on strong CYP3A
inhibitors [14] and consequently this could be the corticosteroid
of choice for patients on HCV protease inhibitors. Dermatically
applied steroids are not expected to cause signiﬁcant systemic
absorption; this could be different for anorectal administration
to treat anorectal discomfort.
Antimicrobial agents (non-HIV)
Ketoconazole is a prototype CYP3A inhibitor often used during
clinical development of putative CYP3A substrates such as tela-
previr and boceprevir to investigate interactions. It has been
shown that telaprevir levels were increased by 62% and also
ketoconazole levels were elevated by 46–125%, demonstrating
telaprevir’s CYP3A/P-gp inhibitory potential [15]. It is recom-
mended that telaprevir can de dosed normally, but that the keto-
conazole dose should not exceed 200 mg/day to avoid
development of toxicity. This recommendation has been
extended to itraconazole although the combination with telapre-
vir was not formally studied. For boceprevir and ketoconazole,
similar effects have been noticed. Consequently maximum doses
of ketoconazole and itraconazole of 200 mg/day are also in the
product label for boceprevir.
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Besides ketoconazole, the macrolide clarithromycin is a well-
known CYP3A inhibitor. Plasma concentrations of boceprevir
were only marginally increased (+21%) during co-administration
and, therefore, these agents can be safely combined without dose
adjustments [16]. Telaprevir has not been tested with clarithro-
mycin, but a similar recommendation can be given. The potential
increase in clarithromycin levels, however, warrants electrocar-
diogram (ECG) monitoring in patients also on telaprevir, as QT
prolongation may occur. Where possible, azithromycin is an
alternative to clarithromycin, as the former macrolide is not a
CYP3A inhibitor or substrate.
Rifampin is the prototype of a strong enzyme inducer and is
often difﬁcult to combine with CYP substrates such as telaprevir
and boceprevir. The AUC of telaprevir in combination with rifam-
pin was reduced by 92% when compared to telaprevir alone, and
this combination is contraindicated [15]. Boceprevir has not been
tested with rifampin, but a contraindication also applies.
Methadone/buprenorphine
Because (former or current) intravenous drug use is a major
transmission route for HCV, a considerable number of patients
who are receiving opiate substitution therapy and/or actively
using illicit drugs will be considered for therapy with DAAs.
Hence there is a risk for a drug–drug interaction. Methadone is
commonly used in opiate substitution programs and has been
extensively studied. Telaprevir reduced methadone levels on
average by 29%, but this effect is most probably attributed to dis-
placement of methadone from plasma protein-binding sites [17].
Free, active concentrations of methadone remained largely
unchanged. A somewhat smaller decrease in methadone levels
was seen with boceprevir: AUC and Cmax were reduced by 22%
and 15%, respectively; free methadone levels were not reported
[18]. Surprisingly, the use of peg-interferon alfa appeared to
cause a small increase in methadone levels of about 15%, which
is unlikely to be associated with the need for a dose reduction
to prevent methadone toxicity. Taking these apparently opposite
effects of telaprevir/boceprevir and peg-interferon alfa together,
close monitoring might be prudent in patients on methadone,
when HCV combination therapy is initiated. Importantly, there
should be a low threshold for methadone dose adjustment based
on patient responses. In some centers, patients and their friends
who are being considered for antiviral therapy are provided with
opiate antagonists (naloxone), along with instructions for their
use and this may be a prudent precaution in individuals with
erratic consumption of illicit opiates.
Buprenorphine is an alternative to methadone for patients
with opiate addiction. It has multiple metabolic pathways,
including CYP3A, so an increase in plasma concentrations was
possible when combined with CYP3A inhibitors such as telaprevir
or boceprevir. However, buprenorphine levels were not increased
when this was combined with telaprevir and also no signs of tox-
icity were observed [19]. Boceprevir caused a minor increase in
buprenorphine AUC (+19%) which was associated with a 45%
decrease in the AUC of norbuprenorphine, demonstrating an
effect of boceprevir on this CYP3A pathway [18]. These changes,
however, are not considered clinically relevant.
Buprenorphine is also available in a ﬁxed-dose combination
with naloxone. Systemic bioavailability of oral naloxone is very
low (<3%) due to extensive ﬁrst-pass metabolism (mainly
UDP-glucuronosyltransferase (UGT) and partly CYP3A). Bocepre-
vir increased naloxone AUC by 33%, suggesting that bioavailabil-
ity of naloxone is somewhat improved when these agents are co-
administered [18].
Antidepressants
It is generally accepted that the use of peg-interferon alfa can
lead to psychiatric disorders including depression. Concomitant
use of antidepressants with HCV treatment will thus not be a rar-
ity and this poses the risk for a drug–drug interaction with DAAs,
as both groups are CYP substrates. Escitalopram has been studied
for the prevention of peg-interferon-induced depression and was,
therefore, a logical candidate to be tested for a drug interaction
with HCV protease inhibitors. With telaprevir, no change
occurred in telaprevir levels, but escitalopram levels were
decreased by an average of 35% [20]. When initiating escitalop-
ram in a patient on telaprevir, one should dose titrate high
enough before concluding that the antidepressant is not effective.
The effect of boceprevir on escitalopram had the same direction
as with telaprevir, although the magnitude of the decrease in
AUC was smaller (17%) [21].
It is unlikely that all patients can be effectively treated with
escitalopram, and clinicians may have preferences for other anti-
depressants based on personal experience. Some of these agents
(e.g., sertraline and mirtazepine) are CYP3A substrates and
increased plasma concentrations of the antidepressant may occur
when combined with telaprevir or boceprevir. Other antidepres-
sants are more selectively metabolised by CYP2D6 (e.g., paroxe-
tine, duloxetine and ﬂuoxetine) and their pharmacokinetics are
expected not to be inﬂuenced by telaprevir and boceprevir as
the latter agents do not possess CYP2D6 inhibitory activity. More
research is needed in this area.
Sedatives
A number of benzodiazepines are heavily dependent on CYP3A
for their metabolism and interactions with boceprevir and tela-
previr can be expected. Midazolam is a prototype CYP3A sub-
strate, but is also relevant here as it is being used as
premedication before endoscopy or gastroscopy. The AUC of oral
midazolam was increased 9-fold with telaprevir [22] and 5.3-fold
with boceprevir [2] and, therefore, oral midazolam is contraindi-
cated with both DAAs. The magnitude of an interaction with
parenteral midazolam is less than that observed with oral midaz-
olam, as the inhibition of presystemic CYP3A metabolism is no
longer relevant. Indeed, midazolam AUC increased only 3.4-fold
when i.v. midazolam was added to telaprevir (vs. 9-fold with oral
midazolam, see above) and there was no change in Cmax of midaz-
olam [22]. Administration of 50% of the normal parenteral dose in
patients on boceprevir or telaprevir is probably safe.
Other oral benzodiazepines such as triazolam and alprazolam
[23] are contraindicated. Zolpidem levels were reduced by
approximately 50% with steady-state telaprevir, so possibly a
higher dose of zolpidem is needed [23]. Ketamine is extensively
metabolised in the liver by various CYP enzymes and conse-
quently, if CYP3A is involved, there are potentially multiple
escape pathways. Propofol is mainly eliminated renally and,
therefore, no interaction with DAAs is expected.
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Statins
Most statins are also CYP3A substrates and, not surprisingly,
CYP3A inhibitors such as telaprevir and boceprevir are expected
to increase statin levels and the associated risk of severe toxicity
such as rhabdomyolysis. Indeed, atorvastatin levels were ele-
vated almost eight times with telaprevir [24]. This combination
is a contra-indication, as is simvastatin, which has not been
tested. The effect of boceprevir on atorvastatin was less strong:
statin levels increased 2.3 times and this interaction appears to
be manageable by starting with a low dose of atorvastatin
(10 mg) [25]. An alternative option might be pravastatin as this
statin is not a CYP substrate. Pravastatin levels were marginally
increased when combined with boceprevir (1.5-fold), probably
caused by inhibition of the organic anion-transporting polypep-
tide (OATP) 1B1 [25,26]. There are no data on rosuvastatin and
HCV protease inhibitors.
Some clinicians have the opinion that, given the relatively
short treatment duration with DAAs, at least with telaprevir
(12 weeks), one can also temporarily stop the statin to avoid tox-
icity associated with a potential drug–drug interaction.
Cardiovascular agents (other than statins)
Calcium entry blockers are known CYP3A (and partly also P-gp)
substrates and thus increased exposure can be expected with
CYP3A inhibitors such as telaprevir and boceprevir. This was also
observed: amlodipine levels increased 1.8-fold when combined
with telaprevir [24]. It is advised to start with a low dose of amlo-
dipine (5 mg) and titrate to the desired effect. Effects of telaprevir
on other calcium channel blockers are expected to be more
severe than this, since most of these agents have a larger
CYP3A-mediated ﬁrst-pass effect. Thus, telaprevir can cause a
more pronounced drug interaction. There are currently no data
on boceprevir and amlodipine, but as boceprevir is also known
as a CYP3A inhibitor (though weaker than telaprevir) a similar
recommendation as with telaprevir appears logical.
Some of the calcium entry blockers have very low systemic
bioavailability (4–8%: barnidipine, lacidipine, lercanidipine) due
to extensive ﬁrst-pass metabolism. However, when combined
with CYP3A inhibitors, such as telaprevir or boceprevir, systemic
exposure may easily increase several-fold; therefore, these agents
should not be used as a ﬁrst choice.
Diuretics, angiotensin converting enzyme inhibitors (ACE) and
angiotensin II receptor antagonists (AT1) are all classes of agents
without extensive CYP metabolism, and hence combination with
telaprevir and boceprevir is not expected to be problematic. b-
receptor blocking agents are also not expected to cause problems
as they are mainly eliminated renally (e.g., atenolol and sotalol)
or metabolised through CYP2D6 (e.g., metoprolol and carvedilol).
Anti-arrhythmics have a narrow therapeutic window and some
are CYP3A substrates (e.g., amiodarone and bepridil). These are
contraindicated with the strong CYP3A inhibitor telaprevir and
caution is warranted with the moderate CYP3A inhibitor
boceprevir.
Digoxin has been tested with telaprevir [22] and boceprevir
[27] as a prototype P-gp substrate: digoxin levels were increased
by 85% with telaprevir so this DAA can be deﬁned as a moderate
P-gp inhibitor and one should start with a low-dose digoxin in a
patient on telaprevir. With boceprevir, the impact on digoxin lev-
els was less than with telaprevir: AUC and Cmax of digoxin were
increased by 19% and 18%, respectively. This suggests that boce-
previr is a very mild P-gp inhibitor.
Antidiabetics
Use of antidiabetics should be monitored carefully in patients
with hepatic impairment to avoid the occurrence of severe hypo-
glycaemia. Repaglinide is one of the few oral antidiabetics that is
partially metabolised by CYP3A and theoretically could interact
with the CYP3A inhibitors boceprevir and telaprevir. Repagli-
nide’s primary route of metabolism, however, is CYP2C8. This
would be the escape pathway in the presence of a CYP3A inhibi-
tor; therefore, no interaction with DAAs through this mechanism
is expected. Repaglinide is also a substrate for OATP transporters
and may consequently interact with DAAs in a non-CYP mediated
mechanism. Some other oral antidiabetics are also metabolised
by the liver, but not the CYP3A iso-enzyme. For instance, glimepi-
ride is a CYP2C9 substrate, but this enzyme is not inﬂuenced by
boceprevir [26] or telaprevir. Metformin is not expected to cause
a problem when combined with DAAs.
Other agents
Finally, in this paragraph some agents are described that did not
fall in one of the main therapeutic areas that are listed above. This
includes either agents that have been tested or those with a con-
traindication based on theoretical considerations.
Plasma concentrations or the estrogen component of oral con-
traceptives are reduced by about 25–30% when combined with
boceprevir [16] or telaprevir [28], and it is recommended to take
additional (non-hormonal) precautions to prevent pregnancy.
This is not only based on the observed drug interaction data,
but also because HCV therapy includes ribavirin, which is terato-
genic. Therefore, pregnancy should also be avoided from that
important perspective.
The following agents are contraindicated with telaprevir and
boceprevir because these agents are strongly dependent on
CYP3A for metabolism and have a narrow therapeutic range:
alfusozin, cisapride, ergotamin and derivates and pimozide.
Colchicine is another CYP3A substrate with a narrow thera-
peutic range; the drug labels contain a dosing algorithm for com-
bined use of DAAs with colchicine, depending on its indication.
Besides rifampin, other strong enzyme inducers are carbam-
azepine, phenytoin, phenobarbital and St John’s wort; these
inducers should not be combined with DAAs to avoid the occur-
rence of subtherapeutic levels of DAAs. Alternative anti-epileptic
agents, such as valproic acid, levetiracetam and lamotrigine, are
not enzyme inducers or CYP3A substrates. Therefore, they should
be easier to combine with DAAs.
Phosphodiesterase type 5 inhibitor (PDE5) inhibitors such as
sildenaﬁl and tadalaﬁl are CYP3A substrates and toxic levels
can occur when combined with telaprevir or boceprevir. When
these agents are applied at high doses for treatment of pulmon-
ary hypertension, they are contraindicated with DAAs. However,
for their use in erectile dysfunction, lower doses and/or less fre-
quent dosing should be safe: sildenaﬁl, 25 mg per 48 h; tadalaﬁl,
10 mg per 72 h; vardenaﬁl, 2.5 mg per 24 h (boceprevir) or
2.5 mg per 72 h (telaprevir). The proton pump inhibitor esomep-
razole does not inﬂuence telaprevir exposure. Ibuprofen and
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diﬂunisal analgesic agents are interesting in this perspective as
they are known to be AKR inhibitors, and AKR is responsible for
part of boceprevir’s metabolism. A drug–drug interaction study,
however, did not show an effect of diﬂunisal or ibuprofen on
boceprevir pharmacokinetics [4].
An overview of the drug interactions with frequently used co-
medications in HCV-infected patients is shown in Table 1.
Limitations of current drug interaction data
Many of the above-mentioned drug–drug interaction studies
have been performed in healthy volunteers to avoid potential
harm to patients who are at risk for toxicity or subtherapeutic
effects when potentially interacting drugs are combined. This
assumes that the effect of a certain drug–drug interaction is sim-
ilar in healthy subjects as in an HCV-infected patient. This might
not always be the case. For instance, HCV-infected patients with
cirrhosis may also have impaired CYP450 capacity and have
higher plasma concentrations of CYP450 substrates than healthy
subjects. Theoretically, this would mean that they are at even
more risk for drug toxicity when a drug–drug interaction occurs
that is based on CYP450 inhibition, but at lower risk for subther-
apeutic effects when a drug–drug interaction is based on enzyme
induction, impaired absorption, etc. Nevertheless, extrapolation
from healthy subjects to patients is still considered to be the
norm, although in individual cases therapeutic drug monitoring,
if available, might be helpful to assess the clinical relevance for
that speciﬁc patient.
Conclusions
This overview illustrates that drug–drug interactions are an
important and potentially frequent problem when using DAAs
in clinical practice. It also shows, however, that many of the inter-
actions are manageable by either dose adjustments or selecting a
safe alternative, but only if one has sufﬁcient knowledge and
expertise to deal with these pharmacokinetic issues. The aim of
this review was to provide this insight, as well as to raise aware-
ness that drug–drug interactions in modern HCV treatment may
have unwanted effects, such as increased toxicity or lack of ther-
apeutic effect. This is of course most likely to have an impact on
patients on multiple medications and/or treated by multiple phy-
sicians. Whenever one doubts about the safety of a certain com-
bination, one should consult a pharmacist or clinical
pharmacologist.
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